ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $138,043,504 | -8.8% | 3,831,349 | +0.0% | 0.04% | -12.2% |
| Q4 2022 | $151,407,443 | -24.6% | 3,831,160 | -23.4% | 0.04% | -30.5% |
| Q3 2022 | $200,833,000 | -4.4% | 4,998,342 | +0.1% | 0.06% | +3.5% |
| Q2 2022 | $209,973,000 | +7.9% | 4,994,607 | +0.0% | 0.06% | +29.5% |
| Q1 2022 | $194,550,000 | -2.1% | 4,993,590 | +0.1% | 0.04% | +4.8% |
| Q4 2021 | $198,803,000 | +10.3% | 4,988,792 | +0.0% | 0.04% | +2.4% |
| Q3 2021 | $180,247,000 | -74.0% | 4,987,467 | -70.6% | 0.04% | -74.2% |
| Q2 2021 | $694,482,000 | -3.2% | 16,942,708 | +3.0% | 0.16% | -12.6% |
| Q1 2021 | $717,510,000 | -12.9% | 16,449,101 | -0.0% | 0.18% | -19.1% |
| Q4 2020 | $823,390,000 | +88.7% | 16,451,353 | +58.6% | 0.22% | +66.7% |
| Q3 2020 | $436,436,000 | +10.5% | 10,374,043 | +27.5% | 0.14% | +4.7% |
| Q2 2020 | $395,054,000 | – | 8,137,055 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |